Ji-Hwan Eom1, Se-Yun Cheon2, Kyung-Sook Chung2, Myung-Dong Kim1, Hyo-Jin An3. 1. Department of Physiology, College of Korean Medicine, Sangji University, Wonju-si Gangwon-do, 220-702, Republic of Korea. 2. Department of Pharmacology, College of Korean Medicine, Sangji University, Wonju-si Gangwon-do, 220-702, Republic of Korea. 3. Department of Pharmacology, College of Korean Medicine, Sangji University, Wonju-si Gangwon-do, 220-702, Republic of Korea. hjan@sj.ac.kr.
Abstract
OBJECTIVE: To evaluate the efficacy of Bawu Decoction (, BWD, Palmul-tang in Korean) against benign prostatic hyperplasia (BPH). METHODS: Twenty-four male Wistar rats were divided into 4 groups, with 6 rats in each group. The 4 study groups included sham-operated group (CON), BPH model group, fifinasteride-treated group, and BWD-treated group. All the groups except CON group received a subcutaneous injection of 10 mg/kg of testosterone, while CON group received saline. Finasteride at a dose of 5 mg/kg was administered to the finasteride-treated group for a period of 4 weeks. BWD group received BWD at a dose of 200 mg/kg for 4 weeks. The prostatic weight, prostate weight to body weight ratio, relative prostate weight ratio, serum testosterone and dihydrotestosterone (DHT) level, and histological analysis of prostatic tissue were analyzed. RESULTS: Compared to BPH model group, BWD administration was associated with reductions in prostatic weight, prostate and relative prostate weight ratio weight to body weight ratio (P<0.05). The concentration of serum testosterone and DHT were higher in BPH group compared with CON group (P<0.05). Administration of finasteride and BWD suppressed the elevation of serum testosterone and DHT levels signifificantly (both P<0.05). In addition, BWD suppressed the growth of prostatic tissue (P<0.05). CONCLUSION: BWD has suppressant effects on development of BPH through inhibition of serum testosterone and DHT.
OBJECTIVE: To evaluate the efficacy of Bawu Decoction (, BWD, Palmul-tang in Korean) against benign prostatic hyperplasia (BPH). METHODS: Twenty-four male Wistar rats were divided into 4 groups, with 6 rats in each group. The 4 study groups included sham-operated group (CON), BPH model group, fifinasteride-treated group, and BWD-treated group. All the groups except CON group received a subcutaneous injection of 10 mg/kg of testosterone, while CON group received saline. Finasteride at a dose of 5 mg/kg was administered to the finasteride-treated group for a period of 4 weeks. BWD group received BWD at a dose of 200 mg/kg for 4 weeks. The prostatic weight, prostate weight to body weight ratio, relative prostate weight ratio, serum testosterone and dihydrotestosterone (DHT) level, and histological analysis of prostatic tissue were analyzed. RESULTS: Compared to BPH model group, BWD administration was associated with reductions in prostatic weight, prostate and relative prostate weight ratio weight to body weight ratio (P<0.05). The concentration of serum testosterone and DHT were higher in BPH group compared with CON group (P<0.05). Administration of finasteride and BWD suppressed the elevation of serum testosterone and DHT levels signifificantly (both P<0.05). In addition, BWD suppressed the growth of prostatic tissue (P<0.05). CONCLUSION: BWD has suppressant effects on development of BPH through inhibition of serum testosterone and DHT.
Authors: C B Brendler; S J Berry; L L Ewing; A R McCullough; R C Cochran; J D Strandberg; B R Zirkin; D S Coffey; L G Wheaton; M L Hiler; M J Bordy; G D Niswender; W W Scott; P C Walsh Journal: J Clin Invest Date: 1983-05 Impact factor: 14.808
Authors: La Yoon Choi; Mi Hye Kim; Yeon Kyung Nam; Ju Hee Kim; Hea-Young Cho; Woong Mo Yang Journal: Front Pharmacol Date: 2021-03-26 Impact factor: 5.810